RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
Working with international thought leaders in risk science, Risk Sciences International investigators contributed to the development of the evidenced-based risk assessment framework shown in the…
Read News ItemProblem Formulation in Food Safety Assessments conducted by the European Food Safety Authority RSI investigators recently provided advise to the European Food Safety Authority (EFSA)…
Read News ItemIn its 2007 report on Toxicity Testing in the 21st Century: A Vision and a Strategy, the US National Research Council (NRC) highlighted need for more rapid…
Read News ItemRSI investigators propose fundamental principles of risk decision-making, and explore their application in a range of real-world risk decision-making contexts. These ten principles will provide valuable guidance on addressing current and future risk issues facing civil societies worldwide.
Read News Item